Role of Withaferin A in the management of breast cancer: A comprehensive review
Keywords:Anticancer, Ashwagandha, Ayurveda, Breast cancer, TNBC, Withania somnifera, Withaferin-A, ER positive, PR Positive
Background: Breast cancer is one of the leading causes for cancer mortality. The conventional treatments are being rprted for many side effects which affects quality of life of a patient. Novel therapeutic and preventative strategies from the medicinal herbs are needed to reduce suffering, disease free survival, and mortality from breast cancer. Withania somnifera L. Dunal (Indian winter cherry or Ashwagandha) from the Solanaceae family is an appealing medicinal plant widely investigated for its breast cancer potential. Ayurveda treaties explained various formulations using root of Ashwagandha. Modern science explained uses of root and leaf in extract forms. Withaferin A is a promising anticancer withanolides. This review is based on in-vitro researches of Withaferin A on breast cancer cell lines like MCF-7 cells, MDA-MB-231, SUM159, MDA-MB-468, SUM149,SUM159, 231MFP supported by its mechanism, in-vivo studies and clinical records. Material and methods: This review is based on various preclinical researches related to breast cancer. Moreover, this review represents the effect of Withaferin A on cancer cell. Various articles including studies and description of Ashwagandha were reviewed using databases namely Google Scholar, PubMed, Web of Science, Scopus. Result:Withaferin A significantly arrests the growth of many breast cancer cell in vivo and in vitro. Conclusion: Ashwagandha is a commonly available, cost effective natural medicine,possess anti-cancer potential. It can serves a add on treatment strategy for breast cancer management, chemoprevention, tumor suppression.
How to Cite
Copyright (c) 2023 International Journal of Ayurvedic Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.